** Atomo Diagnostics AT1.AX soars as much as 11.1% to A$0.020; biggest intraday gain since Dec. 5, 2024
** Medical devices maker executes new long-term supply agreement for its HIV self-test device
** Five-year deal with existing distribution partner Newfoundland Diagnostics worth ~A$5.4 mln ($3.4 mln)
** Deal grants Newfoundland exclusive distribution rights to supply Atomo's test in the UK and non-exclusive rights for the EU and Colombia
** AT1 up 5.3% YTD
($1 = A$1.6184)
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.